Keywords: Johnson & Johnson, Zeltia, Centocor Ortho, Trabectedin, Ovarian cancer, USA, Yondelis

Johnson & Johnson unit voluntarily withdraws NDA for trabectedin

Article | 03 May 2011

Print This

Centocor Ortho Biotech Products, a division of US health care giant Johnson & Johnson (NYSE: JNJ), says it has voluntarily ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in